Posted by Michael Wonder on 23 Dec 2020
FDA approves Bracco Diagnostics' ProHance (gadoteridol) Injection, 279.3 mg/mL, for paediatric patients younger than two years
23 December 2020 - Bracco Diagnostics today announced that the U.S. FDA has approved ProHance (gadoteridol 279.3 mg/mL injection) for intravenous use with magnetic resonance imaging in paediatric patients under two years old, including term neonates, to visualise areas with disrupted blood brain barrier and/or abnormal vascularity throughout the brain, spine and associated tissues.
ProHance was previously approved for this use in patient populations over the age of two.
